J&J 4Q Revenues: $16.0 billion (+17%) 4Q Earnings: $2.4 billion (+10%) FY Revenues: $61.1 billion (+15%) FY Earnings: $10.6 billion (-4%) Comments: Worldwide pharmaceutical sales were up 7% to $24.9 billion for the year. Sales growth was driven by Risperdal, Consta, the launch of Invega, Topamax, Remicade, Velcade, Concerta and Levaquin. Growth was negatively impacted by lower Procrit sales. R&D expenses for the year were $7.7 billion, up 8%. 4Q and FY domestic sales were ...